A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer
Gastric Cancer
Stomach Cancer
Gastroesophageal Junction Cancer
Esophageal Cancer
Hepatocellular Carcinoma
Melanoma
Uveal Melanoma
Merkel Cell Carcinoma
Mesothelioma
MSI
Non-small Cell Lung Cancer
NSCLC
Ovarian Cancer
Squamous Cell Carcinoma of the Head and Neck
Small Cell Lung Cancer
Renal Cell Carcinoma
RCC
Triple-negative Breast Cancer
Urothelial Carcinoma
Mismatch Repair Deficiency

Interventions

DRUG: INCAGN02390

Sponsor

Incyte Corporation